Arrowstreet Capital Limited Partnership Purchases 1,185,909 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Arrowstreet Capital Limited Partnership boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 698.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,355,609 shares of the biopharmaceutical company’s stock after purchasing an additional 1,185,909 shares during the quarter. Arrowstreet Capital Limited Partnership owned about 1.03% of Alnylam Pharmaceuticals worth $618,158,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently made changes to their positions in the business. Root Financial Partners LLC bought a new position in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $25,000. Salomon & Ludwin LLC bought a new position in Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $27,000. Ameriflex Group Inc. bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth approximately $32,000. Aster Capital Management DIFC Ltd bought a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth about $36,000. Finally, ORG Partners LLC raised its stake in Alnylam Pharmaceuticals by 70.2% during the 3rd quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 33 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, EVP Jeffrey V. Poulton sold 2,780 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.87, for a total transaction of $1,008,778.60. Following the sale, the executive vice president owned 57,465 shares in the company, valued at approximately $20,852,324.55. The trade was a 4.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Yvonne Greenstreet sold 9,577 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.86, for a total transaction of $3,475,110.22. Following the completion of the sale, the chief executive officer owned 78,411 shares of the company’s stock, valued at approximately $28,452,215.46. This trade represents a 10.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 53,923 shares of company stock valued at $18,072,087. Corporate insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Canaccord Genuity Group upped their price target on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Morgan Stanley dropped their target price on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research report on Friday, January 30th. Needham & Company LLC cut their price target on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Chardan Capital cut their price objective on shares of Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. Finally, Leerink Partners dropped their price objective on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $477.96.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $317.23 on Friday. The firm has a market capitalization of $42.07 billion, a P/E ratio of 185.51 and a beta of 0.36. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. The stock’s fifty day moving average is $346.09 and its two-hundred day moving average is $410.94. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. During the same quarter in the previous year, the company posted ($0.65) earnings per share. The company’s revenue was up 84.9% on a year-over-year basis. On average, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.